StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
31F.F$10.70+0.00%
Fair $10.70+0.0%

31F.F

Medical Facilities Corporation

Healthcare / Medical Care FacilitiesFrankfurt

$10.70

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $10.70Fund rank 34/100 · Data gapFallback financials|
SA 47/C
F-Score: 3/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $56.7M · quality 67.0/100

Data gap 34/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 31F.FLocal privado en este navegador · Medical Facilities Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$188M

P/E

14.3x

↓

EV/EBITDA

3.5x

↓

ROE

28.2%

↑

Gross Margin

69.9%

↑

Debt/Equity

0.78

↑
52-Week Range$11
$8$11

TradingView lightweight chart

31F.F price, volumen y niveles de valoración

Último $10.50Periodo -6.0%
Fair value: $10.70

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-15.7%

FCF CAGR

-7.1%

FCF margin

15.8%

FCF / Net income

1.90x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $254.2M · net income $21.3M · FCF $40.3M

2022-FY → 2025-FY

Gross margin

69.9%+3.8% pts

Operating margin

18.4%+6.2% pts

Net margin

8.4%+9.4% pts

FCF margin

15.8%+4.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$254.2M$254.2M$246.1M$339.6M$424.6M
Net Income$21.3M$21.3M$73.5M$18.5M$-4.4M
EBITDA$64.2M$64.2M$73.3M$72.4M$51.2M
EPS1.091.093.060.73-0.15
Gross Margin69.9%69.9%70.4%64.6%66.1%
Operating Margin18.4%18.4%21.3%14.5%12.1%
Net Margin8.4%8.4%29.9%5.4%-1.0%
Balance Sheet
Debt/Equity0.780.780.611.361.81
Current Ratio2.082.08———
Cash Flow
Free Cash Flow$40.3M$40.3M$76.2M$56.7M$50.3M
Returns
ROE28.2%28.2%60.2%21.5%-5.6%
Valuation
P/E14.2714.273.378.56—
EV/EBITDA3.493.492.903.465.33
P/B2.762.762.031.842.08
Growth & Yield
Revenue Growth3.3%3.3%-27.5%-20.0%—
EPS Growth-64.4%-64.4%319.2%586.7%—
Dividend Yield2.1%2.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

-4.5%

fácil

EPS terminal req.

$0.95

Spread vs growth

-59.9%

5Y implied EPS CAGR

1.1%

fácil

EPS terminal req.

$1.15

Spread vs growth

-65.4%

10Y implied EPS CAGR

5.4%

razonable

EPS terminal req.

$1.85

Spread vs growth

-69.8%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.1%

Total return

+7.1%

Start / end P/E

3.3x → 9.6x

EPS bridge

3.06 → 1.09

Residual

-125.4%

EPS growth-64.4%
Multiple rerating+194.8%
Dividend+2.1%
Residual / FX / buybacks / cross-term-125.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.